EUVIMEDOpdag EUVIMED
Multizentrische StudieKohortenstudie

Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study

Mathurin Fumery iD, Antoine Defrance, Xavier Roblin iD, Romain Altwegg iD, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer iD, Maria Nachury, David Laharie iD, Stephane Nancey, Catherine Le Berre and 13 more

Alimentary Pharmacology & Therapeutics · 2023-02 · 57 (4) · 426-434

DOI: 10.1111/apt.17358 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2022-12-19. Written by Mathurin Fumery and 24 co-authors. Institution: Department of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France. Major MEDLINE topics: Crohn Disease. Cited 37 times so far (Crossref); 15 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Phase III trials have demonstrated the efficacy of risankizumab in moderate‐to‐severe Crohn's disease (CD), but no real‐world data are currently available. We aimed to assess the short‐term effectiveness and safety of risankizumab in patients with CD.

Methods

From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid‐free clinical remission at week 12 (Harvey‐Bradshaw [HB] score

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseHumansUstekinumabInduction ChemotherapyRetrospective StudiesTumor Necrosis Factor InhibitorsRemission InductionTreatment OutcomeAntibodies, Monoclonal

Author keywords

Crohn’s diseaseeffectivenessinduction therapyrisankizumab

Substances

UstekinumabTumor Necrosis Factor InhibitorsrisankizumabAntibodies, Monoclonal

Authors and institutions

  • Department of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France.
  • Groupe d'étude des Affections Inflammatoires du tube Digestif, GETAID, Paris, France.
  • Department of Gastroenterology, CHU of Saint-Etienne, Saint-Etienne, France.
  • Department of Gastroenterology, CHU of Montpellier, Montpellier, France.
  • Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France.
  • Department of Gastroenterology and Clinical Nutrition, CHU of Nice and University Côte d'Azur, Nice, France.

ORCID profiles: Mathurin Fumery, Xavier Roblin, Romain Altwegg, Antoine Meyer, David Laharie, Mathieu Uzzan, My-Linh Tran-Minh, Lucine Vuitton, Laurent Peyrin-Biroulet

Cite

APA

Fumery, M., Defrance, A., Roblin, X., Altwegg, R., Caron, B., Hébuterne, X., Stefanescu, C., Meyer, A., Nachury, M., Laharie, D., Nancey, S., Le Berre, C., Serrero, M., Geyl, S., Giletta, C., Ah-Soune, P., Duveau, N., Uzzan, M., Abitbol, V., …, & Peyrin-Biroulet, L. (2023). Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary Pharmacology & Therapeutics, 57(4), 426-434. https://doi.org/10.1111/apt.17358

Vancouver

Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary Pharmacology & Therapeutics. 2023;57(4):426-434. doi:10.1111/apt.17358

BibTeX
@article{Fumery2023,
  author = {Fumery, Mathurin and Defrance, Antoine and Roblin, Xavier and Altwegg, Romain and Caron, Benedicte and Hébuterne, Xavier and Stefanescu, Carmen and Meyer, Antoine and Nachury, Maria and Laharie, David and Nancey, Stephane and Le Berre, Catherine and Serrero, Melanie and Geyl, Sophie and Giletta, Cyrielle and Ah-Soune, Philippe and Duveau, Nicolas and Uzzan, Mathieu and Abitbol, Vered and Biron, Amelie and Tran-Minh, My-Linh and Paupard, Thierry and Vuitton, Lucine and Elgharabawy, Yasmine and Peyrin-Biroulet, Laurent},
  title = {Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {4},
  pages = {426--434},
  doi = {10.1111/apt.17358}
}
Start for free →